GLP-1 medications mimic a gut hormone your body makes after eating. They increase fullness, reduce appetite and "food noise," slow stomach emptying, and improve blood sugar. Newer drugs also activate a second hormone (GIP). They treat the biology that defends weight — which is why they work when willpower alone often can't — and why weight tends to return if they're stopped.
Why these drugs are different
Most weight-loss approaches fight the body's defense of its weight from the outside. GLP-1 and GLP-1/GIP medications work from the inside — by replacing satiety signals the body under-produces. That's why they've changed obesity medicine: for the first time, medications produce weight loss approaching what was once only surgical, by targeting appetite biology directly rather than relying on discipline.
This hub explains the class. The individual drug pages go deeper. → Semaglutide · Tirzepatide
The physiology (what GLP-1 and GIP actually do)
GLP-1 (glucagon-like peptide-1) is an incretin hormone released by the gut after meals. Its relevant effects:
- Appetite & satiety — acts on the brain (hypothalamus and hindbrain) to increase fullness and reduce hunger.
- "Food noise" — many patients report the constant background pull of food quieting. → Food Noise
- Gastric emptying — slows stomach emptying, so meals feel filling for longer (also the source of early nausea).
- Glucose regulation — stimulates insulin only when glucose is high (so low blood-sugar risk is low on its own) and suppresses glucagon.
GIP (glucose-dependent insulinotropic polypeptide) is a second incretin. Adding GIP activity (as tirzepatide does) appears to further improve appetite regulation and metabolic effects, and in head-to-head data produced greater weight loss than GLP-1 alone. The exact reasons GIP agonism helps are still being worked out. → Tirzepatide
Where things stand (as of this update)
Approved for chronic weight management: - Semaglutide — injectable Wegovy (weight) / Ozempic (type 2 diabetes, same molecule); and now an oral 25 mg tablet approved for weight management (the first oral GLP-1 for obesity). → Semaglutide - Tirzepatide — injectable Zepbound (weight, and moderate-to-severe obstructive sleep apnea with obesity) / Mounjaro (type 2 diabetes). A GLP-1/GIP dual agonist. → Tirzepatide - Liraglutide — injectable Saxenda (weight) / Victoza (diabetes); older, daily, less potent. → Medication Library
Beyond weight — expanding indications: - Cardiovascular: semaglutide 2.4 mg reduced major cardiovascular events in people with established cardiovascular disease and overweight/obesity without diabetes (SELECT trial). This is a landmark: benefit tied to more than weight. → Obesity & Cardiovascular Health - Liver: semaglutide 2.4 mg is now FDA-approved for noncirrhotic MASH with moderate-to-advanced (F2–F3) fibrosis — an accelerated approval. It reduces liver fat and improves MASH; effects on fibrosis are more modest and still maturing. → GLP-1 & Fatty Liver - Sleep apnea: tirzepatide is approved for moderate-to-severe OSA in adults with obesity (SURMOUNT-OSA).
On the horizon (not a treatment yet): triple agonists (retatrutide), GLP-1/amylin combinations (CagriSema), GLP-1/glucagon (survodutide), oral non-peptide GLP-1s (orforglipron). Covered honestly, by development phase, in → The Next Generation of Obesity Drugs.
How much weight — with the context that's usually missing
Weight-loss percentages are meaningless without their trial context. Here are the anchor numbers, stated properly:
- Semaglutide 2.4 mg (STEP 1 trial; adults with obesity, no diabetes; 68 weeks): ~15% mean total body-weight loss, versus ~2.4% on placebo. Placebo-adjusted ≈ 12–13%.
- Tirzepatide (SURMOUNT-1; adults with obesity, no diabetes; 72 weeks): ~15%, ~19.5%, ~20.9% mean at 5, 10 and 15 mg respectively, versus ~3% placebo.
- Head-to-head (SURMOUNT-5; 72 weeks): tirzepatide ~20.2% vs semaglutide ~13.7% — tirzepatide produced greater average loss.
- In type 2 diabetes, weight loss is smaller for both drugs than in obesity-without-diabetes trials — an important, frequently-omitted caveat.
Three rules for reading any of these: 1. These are trial averages; individual results range widely — some people lose far more, some much less, some don't respond. 2. Results depend on reaching and tolerating the studied dose, plus lifestyle support that trials provide. 3. Total vs placebo-adjusted loss are different numbers; marketing often quotes the bigger one without saying which.
→ Full breakdowns on the Semaglutide and Tirzepatide pages.
Side effects, honestly (overview)
Most side effects are gastrointestinal and dose-related: nausea, vomiting, diarrhea, constipation, reflux. They're usually worst during dose escalation and improve with time, slow titration, and smaller/lower-fat meals. Serious but uncommon concerns include gallbladder disease, pancreatitis (rare), and dehydration from severe GI symptoms.
Frequently-asked, frequently-distorted concerns — thyroid cancer, pancreatitis, gastroparesis, muscle loss, hair loss, depression, "Ozempic face" — are addressed with the actual evidence on the → GLP-1 Side Effects and GLP-1 & Muscle Loss pages. Short version: the class has a large, growing safety record; the biggest real-world problems are GI tolerance, muscle preservation, and what happens when you stop.
The hardest question: do you take them forever?
Obesity is chronic, and these drugs treat it while they're present. In trials, stopping the medication led to substantial weight regain and reversal of metabolic improvements over the following year — the defended set point reasserts itself. That doesn't mean everyone needs a lifelong high dose:
- Some people maintain on a lower dose; others need the full dose to hold their result.
- A minority sustain much of their loss with intensive lifestyle support after stopping.
- The framing that fits the evidence is chronic-disease management, like blood-pressure or cholesterol medication — not a temporary "kickstart." Planning maintenance is part of starting. → Weight Regain & Maintenance
We don't claim every patient requires lifelong medication. We do claim that stopping usually means regain, and that you should decide with that reality in view.
SIGNATURE — "What the evidence says: GLP-1 medications"
- What we know: They produce large average weight loss, improve glucose, and — for semaglutide — reduce cardiovascular events and improve MASH. Safety is well characterized for GI effects.
- What we think: Benefits extend beyond weight (heart, liver, possibly kidney and more), and dual/triple agonists will push efficacy higher.
- What we don't know: Very-long-term (decade-plus) outcomes, best long-term maintenance dosing, full effects on fibrosis, and long-term muscle/bone outcomes are still being studied.
- What patients should do: Treat the decision as managing a chronic disease — clarify your goal, weigh contraindications, protect muscle, and plan for maintenance from the start.
Questions patients ask
Are GLP-1s safe?
For most eligible patients, the class has a large and reassuring safety record, with GI effects as the main issue. "Safe" always depends on the individual and contraindications. Grade A 🟢
Are GLP-1s dangerous?
Serious harms are uncommon. Most scary headlines describe rare events or misrepresent trial data. The honest answer is "generally well-tolerated, with real but manageable risks." Grade A/B 🟢 → Side Effects
Can you use a GLP-1 without diabetes?
Yes — Wegovy and Zepbound are specifically approved for weight management in people without diabetes, and SELECT showed cardiovascular benefit in that group. Grade A 🟢
Are GLP-1s "cheating"?
No. They change the biology that defends weight. Calling medication "cheating" reflects stigma, not medicine — we don't say that about blood-pressure pills. Grade A 🟢
What is "food noise"?
The intrusive, near-constant mental preoccupation with food many people describe. Reduced food noise is one of the most consistent patient-reported effects of GLP-1 therapy. Grade B 🟡 → Food Noise
Will I regain the weight if I stop?
Most people regain a substantial portion after stopping, as the defended set point reasserts. Maintenance strategy matters. Grade A 🟢 → Weight Regain
Can semaglutide and tirzepatide be combined?
No — they're not used together. Both are GLP-1 receptor agonists; combining them adds risk without a proven benefit. Choosing between them is the real question. Grade A 🟢 → Semaglutide vs Tirzepatide
Are compounded versions the same?
No — compounded GLP-1s are not FDA-approved products and raise real quality, dosing and safety questions that deserve a careful look, not a slogan. Grade B 🟡 → Compounded GLP-1s
Do GLP-1s cause thyroid cancer?
Rodent studies showed thyroid C-cell tumors; this has not been established in humans, but the drugs carry a boxed warning and are avoided in people with medullary thyroid cancer or MEN2. Grade C 🟠 → Side Effects
KEEP READING (Related block / spoke map)
- Semaglutide — the molecule behind Ozempic and Wegovy, in full.
- Tirzepatide — the GLP-1/GIP dual agonist (Mounjaro/Zepbound), and the comparison.
- GLP-1 Side Effects — every common and feared effect, graded.
- GLP-1 & Muscle Loss — what "lean mass" numbers actually mean.
- Weight Regain & Maintenance — the "forever?" question, answered.
- Should I Take a GLP-1? — a decision tool, not a sales quiz.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: [date] · References: STEP program (semaglutide); SURMOUNT program (tirzepatide); SURMOUNT-5 head-to-head; SELECT (CV outcomes); ESSENCE (MASH); FDA prescribing information. Regulatory status verified at publication and re-checked on update.
